| abstract |
Compounds which form covalent bonds with bruton tyrosine kinase (Btk) are disclosed herein. Non-irreversible inhibitors of Btk are also described herein. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions comprising such compounds. Disclosed are methods for using Btk inhibitors alone or in combination with other therapeutic agents for the treatment of autoimmune diseases or conditions, different immune diseases or conditions, cancers including lymphomas, and inflammatory diseases or conditions. |